Novo Nordisk Raises Sales-Growth Outlook; US Shares Jump Nearly 5%
Novo Nordisk improved its sales outlook, raising the top end of sales-growth guidance to 2% from a prior level. Its U.S.-traded shares rose nearly 5% Wednesday, their largest increase since June.
By Alex JaninNovo Nordisk's U.S.-traded shares were up nearly 5% Wednesday, their largest increase since June, after the Danish drugmaker improved its sales outlook.The company reported a "beat-and-raise" quarter in which executives bumped up the top end of sales-growth guidance to 2%, up from a pr…